267 related articles for article (PubMed ID: 8321084)
1. 5HT2-receptors and serotonin release: their role in human platelet aggregation.
Cerrito F; Lazzaro MP; Gaudio E; Arminio P; Aloisi G
Life Sci; 1993; 53(3):209-15. PubMed ID: 8321084
[TBL] [Abstract][Full Text] [Related]
2. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
Bevan J; Heptinstall S
Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
[TBL] [Abstract][Full Text] [Related]
3. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
De Clerck F; Xhonneux B
Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
[TBL] [Abstract][Full Text] [Related]
4. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
Killam AL; Cohen ML
Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
de Clerck F; David JL; Janssen PA
Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
McBride PA; Mann JJ; Nimchinsky E; Cohen ML
Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
[TBL] [Abstract][Full Text] [Related]
7. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
De Clerck F; Xhonneux B; Leysen J; Janssen PA
Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
[TBL] [Abstract][Full Text] [Related]
8. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
Amstein R; Fetkovska N; Pletscher A; Bühler FR
J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
[TBL] [Abstract][Full Text] [Related]
9. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
10. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists.
Shattil SJ; Budzynski A; Scrutton MC
Blood; 1989 Jan; 73(1):150-8. PubMed ID: 2535942
[TBL] [Abstract][Full Text] [Related]
11. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
[TBL] [Abstract][Full Text] [Related]
13. The efflux of 86Rb and [3H]5-HT from human platelets during continuous perfusion: effects of potassium-induced membrane depolarization and thrombin stimulation.
Andersson TL; Vinge E
Acta Physiol Scand; 1991 Mar; 141(3):421-8. PubMed ID: 1858513
[TBL] [Abstract][Full Text] [Related]
14. Epinephrine potentiates human platelet activation but is not an aggregating agent.
Lanza F; Beretz A; Stierlé A; Hanau D; Kubina M; Cazenave JP
Am J Physiol; 1988 Dec; 255(6 Pt 2):H1276-88. PubMed ID: 3202191
[TBL] [Abstract][Full Text] [Related]
15. Covalent complexes of albumin with serotonin, ketanserin and lysergic acid antagonize the activity of serotonin in human platelets.
VandenBerg SR; Gonias SL
Life Sci; 1989; 44(23):1777-85. PubMed ID: 2733551
[TBL] [Abstract][Full Text] [Related]
16. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
18. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
19. Alternate complement pathway induction of aggregation and release of 5-hydroxytryptamine and adenosine diphosphate by rabbit platelets.
Marney SR; Colley DG; Des Prez RM
J Immunol; 1975 Feb; 114(2 Pt 1):696-703. PubMed ID: 804512
[TBL] [Abstract][Full Text] [Related]
20. Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate.
Heptinstall S; Mulley GP
Br J Haematol; 1977 Aug; 36(4):565-71. PubMed ID: 889719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
